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Abstract
Aims/hypothesis By combining multiple genome-wide as-
sociation (GWA) studies and comprehensive replication
efforts, 12 novel type 2 diabetes associated loci have
recently been discovered. Here we evaluate the effect of
lead variants of these loci on estimates of insulin release
and insulin resistance derived from an oral glucose
tolerance test.
Methods We examined 12 lead variants in or near HMGA2,
CENTD2 (also known as ARAP1), KLF14, PRC1,
TP53INP1, ZBED3, ZFAND6, CHCHD9, DUSP9, KCNQ1,
BCL11A and HNF1A in 5,722 middle-aged people from the
population-based Inter99 sample.
Results Carriers of the major diabetogenic allele of
rs1552224 in CENTD2 had increased 30-min plasma
glucose values (2.0%, p=2×10−5) as well as 4.2% reduced
insulin release 30 min after an oral glucose load (p=0.001).
Risk allele carriers also had decreased BIGTT-acute insulin
release (AIR), which is a surrogate measure of insulin
release where sex, BMI, plasma glucose and serum insulin
are integrated (5.3%, p=8×10−7). In addition, a decreased
corrected insulin response (CIR; 9.9%, p=3×10−8)
was observed. For rs5945326 near DUSP9 on the
X-chromosome we stratified according to sex. Male carriers
of the risk allele showed nominally decreased BIGTT-AIR
(2.6%, p=0.01). No associations with intermediate meta-
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bolic traits were found in women. For the remaining ten
lead variants no consistent associations were demonstrated.
Conclusions/interpretation Of the lead variants from 12
novel type 2 diabetes associated loci, CENTD2 significantly
associated with increased plasma glucose values and
decreased glucose-stimulated insulin release, suggesting
that the diabetogenic effect of this locus is mediated
through an impaired pancreatic beta cell function.
Keywords Association study . Beta cell function . Genetic
epidemiology . Type 2 diabetes
Abbreviations
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DI Disposition index
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Meta-analysis Consortium
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Introduction
Since 2007, the list of common validated type 2 diabetes
genes has grown substantially due to the results of genome-
wide association (GWA) studies. The Diabetes Genetics
Replication and Meta-analysis (DIAGRAM) consortium
have, in 2008 and 2010, reported results from large meta-
analyses [1, 2]. In the latest extended analysis (referred to
as DIAGRAM+) 12 novel type 2 diabetes genes were
discovered [2]; however, these novel loci affect disease risk
modestly with odds ratios between 1.06 and 1.14 [2]. Only
rs5945326, near DUSP9 on the X chromosome, seems to
have an effect size comparable to some of the loci
discovered in the earlier studies (combined odds ratio 1.27).
Due to the sparse knowledge concerning the diabetes-
causing mechanisms of the newly identified variants, the aim
was to explore the intermediate phenotypes that may explain
the observed disease association. Hence, we characterised the
influence of these variants on surrogate measures of beta cell
function and insulin sensitivity derived from an OGTT in a
random population of middle-aged Danes.
Methods
Study population All analyses were conducted in non-
diabetic people from the Inter99 Study sample [3]. Clinical
characteristics and a description of the Inter99 Study
population are shown in Electronic supplementary material
(ESM) Study population and ESM Table 1. Informed
written consent was obtained prior to investigation. The
study was conducted in accordance with the principles of
the Helsinki Declaration II.
Derived estimates of insulin release and insulin sensitivity
from an OGTT The insulinogenic index, BIGTT-acute
insulin response (AIR) and the corrected insulin response
(CIR) were reported as indices of oral glucose-stimulated
insulin release. The insulinogenic index was calculated as
follows: serum insulin30min  serum insulin0min pmol=l½ ð Þ=
plasma glucose30min mmol=l½ . CIR was calculated as:
serum insulin30min pmol=lf g=6:945½   100ð Þ= plasma glucose30minð
mmol=lf g  plasma glucose30min mmol=lf g½ 3:89Þ [4].
The BIGTT indices integrate information on sex and
BMI, combined with plasma glucose and serum insulin,
during an OGTT and were calculated as reported [5]. The
surrogate measures of insulin sensitivity, BIGTT sensitivity
index (SI) and the homeostasis model assessment of insulin
resistance (HOMA-IR) ([plasma glucose0 min (mmol/l)×
serum insulin0 min (pmol/l)]/22.5), respectively, were
calculated as reported [5, 6]. Two different disposition
indices (DIs) were calculated based on the OGTT; for DI 1
we multiplied BIGTT-AIR with BIGTT-SI and for DI 2 we
divided CIR by HOMA-IR.
Genotyping All variants were genotyped by KASPar SNP
Genotyping (KBiosciences, Hoddesdon, UK). All success
rates were above 95% and all error rates below 0.85% in
591 duplicates. All variants were in Hardy–Weinberg
equilibrium in the Inter99 Study (p>0.005).
Statistical analysis The effects of 12 lead variants on
quantitative traits related to type 2 diabetes were analysed
using linear regression models under an additive model.
Values for plasma glucose, serum insulin and derived
indices (except BIGTT-SI), were logarithmically (loge)
transformed before analyses. To investigate the interaction
between sex and DUSP9 rs5945326 we included an
interaction term (sex×genotype) in the linear model in
addition to the main effects. Correction for multiple testing
was performed by Bonferroni (correcting for 12 SNPs), and
a p value below 0.004 was considered significant. A p
value between 0.05 and 0.004 was considered nominally
significant. All statistical analyses were performed with the
statistical programming language R (version 2.10.1) (www.
r-project.org).
Statistical power calculations Statistical power for quanti-
tative traits was estimated using simulations. An additive
genetic model was used for both the simulation of the data
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and for testing the data using a linear model. We used the
empirical variance of the observed traits (insulinogenic
index and HOMA-IR) to simulate phenotypes from the
normal distribution so that variance across genotypes is
drawn from the estimated variance.
Since no prior studies have assessed the effect size of the
OGTT-derived estimate of insulinogenic index and HOMA-
IR on the 12 SNPs, we included the calculated effect sizes
from the Inter99 Study population. Given a study sample of
5,000, CENTD2 (also known as ARAP1) rs1552224 is the
only novel SNP with statistical power above 80% to find the
observed effect size for the insulinogenic index (ESM
Table 2).
In addition, a complementary method to calculate statisti-
cal power was applied. We used the allele frequencies of the
12 novel type 2 diabetes genes and a sample size of 5,722
individuals to estimate the effect size for each allele for which
we had 80% statistical power to detect an association in the
given quantitative trait. We carried out 5,000 simulations and
applied a significance threshold of 0.004. We had 80%
statistical power to detect an allelic difference of 5.4–9.7%
in CIR, 2.8–5.3% in BIGTT-AIR and 0.27–0.51 absolute
difference in BIGTT-SI, respectively.
Results
In case–control settings, seven of the 12 variants that were
reported to reach genome-wide significance in the DIA-
GRAM+ meta-analysis were nominally associated with
type 2 diabetes in the Danish population (p<0.05). These
results are part of the DIAGRAM+ meta-analysis [2], but
are shown in the ESM for comparison (ESM Table 3).
In the population-based Inter99 Study sample of 5,722
individuals, carriers of the major diabetogenic allele of
rs1552224 near CENTD2 had a 4.2% lower 30-min serum
insulin release (95% CI 1.7–6.7, p=0.001) per risk allele
Table 1 Anthropometrics and quantitative metabolic traits during an OGTT in the population-based sample of 5,529 middle-aged Danes stratified
according to rs1552224 at CENTD2
rs1552224 TT (carriers of non-
risk allele)
TG (carriers of one
risk allele)
GG (carriers of two
risk alleles)
Per-risk-allele effect
size (95% CI)
padd padj
n (men/women) 172 (84/88) 1,619 (807/812) 3,738 (1,823/1,915)
Age (years) 45±7 46±8 46±8
BMI (kg/m2) 26.1±4.5 26.1±4.5 26.0±4.3 −0.077 (−0.29, 0.13) 0.5
Plasma glucose (mmol/l)
Fasting 5.4±0.5 5.4±0.5 5.5±0.5 0.57 (0.16, 0.98) 0.007
30 min post OGTT 8.3±1.7 8.4±1.6 8.6±1.7 1.97 (1.07, 2.88) 2×10−5
120 min post OGTT 5.80±1.5 6.0±1.5 6.0±1.6 0.38 (−0.85, 1.61) 0.6
Serum insulin (pmol/l)
Fasting 35 (24–51) 34 (24–51) 33 (23–49) −0.82 (−3.31, 1.66) 0.5
30 min post OGTT 250 (201–342) 258 (183–375) 240 (173–287) −4.19 (−6.70, −1.67) 0.001
120 min post OGTT 145 (84–233) 152 (97–250) 154 (93–244) −0.29 (−3.90, 3.32) 0.9
Insulinogenic index 27 (18–40) 27 (18–40) 24 (17–35) −6.92 (−9.78, −4.07) 2×10−6 2×10−6
HOMA-IR 8.0 (5.7–13.1) 8.2 (5.7–12.4) 8.0 (5.5–12.2) −0.26 (−2.86, 2.35) 0.9
BIGTT-AIR 1,745 (1,380–2,261) 1,696 (1,344–2,182) 1,600 (1,280–2,035) −5.27 (−7.36, −3.18) 8×10−7 3×10−7
BIGTT-SI 9.37±3.75 9.40±4.03 9.48±3.93 0.072 (−0.31, 0.27) 0.5
CIR 111.1 (69.1–186.4) 102.6 (65.1–175.6) 92.8 (57.8–149.3) −9.88 (−13.37, 6.40) 3×10−8 9×10−8
DI 1 15,970 (10,980–
20,240)
15,600 (11,130–
16,220)
14,890 (10,700–
19,720)
−3.83 (−6.33, −1.34) 0.003
DI 2 13.2 (7.4–23.3) 12.5 (6.9–22.0) 11.0 (6.3–19.9) −9.15 (−13.12, −5.15) 8×10−6
Data are means±SD, median (interquartile range), or per-risk-allele effect size (95% CI)
Units of effect sizes are kg/m2 (BMI), no units (BIGTT-SI) or% (all other traits)
BIGTT indices integrate information on sex and BMI combined with plasma glucose and serum insulin during an OGTT to provide indices for
AIR and SI and were calculated as reported [5]
Values of serum insulin and plasma glucose, as well as derived indices of insulinogenic index, HOMA-IR, BIGTT-AIR, CIR, DI 1 and DI 2 were
logarithmically transformed before analysis
Calculated effect sizes and p values (padd) were adjusted for age (BIGTT-SI, BIGTT-AIR and DI 1) or age, sex and BMI (all other traits) assuming
an additive model
For indices of insulin release, HOMA-IR has been added to the model as an independent variable (padj)
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following an OGTT (Table 1). In addition, carriers of the
same risk allele had nominally higher fasting and signifi-
cantly higher 30-min plasma glucose levels (0.6% [95% CI
0.2–1.0, p=0.007] and 2.0% [95% CI 1.1–2.9, p=2×10−5],
respectively). Surrogate measures of insulin release such as
the insulinogenic index, BIGTT-AIR and CIR were signif-
icantly decreased (p=2×10−6, p=8×10−7 and p=3×10−8,
respectively) for the major diabetogenic risk allele of
CENTD2 rs1552224; these findings are consistent with a
decrease in two estimates of OGTT-based disposition indices
(DI 1 3.9% [95% CT 1.3–6.3, p=0.003]; DI 2 9.2% [95% CI
5.2–13.1, p=8×10−6]; Table 1). The results remained largely
unchanged when we added HOMA-IR to the model as a
covariate in the analyses of indices of insulin release
(Table 1).
Of the remaining 11 SNPs, 10 demonstrated no convincing
association with any quantitative traits related to insulin
release or insulin sensitivity (ESM Table 4). DUSP9
rs5945326 was analysed further because of its location on
the X-chromosome. When we stratified according to sex, we
found nominal associations with indices of insulin release in
men (n=2,694). Male risk allele carriers had nominally
lower BIGTT-AIR, (2.6% [95% CI 0.6–4.5, p=0.01]) and,
when adding HOMA-IR as a covariate, the association with
BIGTT-AIR (2.8% [95% CI 1.0–4.6, p=0.002]) was
strengthened. A tendency towards a decrease in CIR and
the two disposition indices was also observed (p<0.06; ESM
Table 5). We did not find associations with any quantitative
trait in women (ESM Table 5). We also examined for
interaction between sex and DUSP9 genotype, and found
indications of different association patterns for traits related
to beta cell dysfunction, indicating stronger effects of the
genotype in men (ESM Table 5).
Discussion
We report the association testing of 12 recently discovered
type 2 diabetes risk variants with intermediary diabetes-
related phenotypes in middle-aged individuals. Our results
suggest an impairment of pancreatic beta cell function for
diabetes risk alleles of the lead variant (rs1552224) at
CENTD2. In addition, we provide suggestive evidence that
rs5945326, near DUSP9 on the X-chromosome, is mediat-
ing its effect through reduced beta cell function in men. As
for the remaining ten type 2 diabetes susceptibility loci, no
convincing associations were established to the surrogate
measurements of beta cell function or insulin sensitivity in
this Danish population-based study.
The DIAGRAM+ consortium provided a new under-
standing of the potential physiological roles of the 12 new
type 2 diabetes susceptibility loci by running quantitative
trait studies of fasting plasma glucose and fasting serum
insulin levels [2]. The majority of SNPs showed higher
fasting glucose for type 2 diabetes risk alleles. In addition,
the lead variant of KLF14 showed an increased fasting
serum insulin level, suggesting a primary insulin desensi-
tising effect, whereas the diabetes associated variants at
CENTD2 associated with reduced fasting serum insulin
concentrations indicating reduced beta cell function. How-
ever, in the DIAGRAM+ Study, only two of these 12 new
loci showed significant association to surrogate measures of
insulin release and insulin sensitivity, as the risk allele at
CENTD2 associated with a lower HOMA-B, and the risk
allele at KLF14 associated with a higher HOMA-IR [2].
Although we recognise HOMA-B as a widely used measure
of beta cell capacity, it is important to emphasise that this
surrogate measure reflects insulin release under non-
stimulated conditions [7], whereas, in the present report,
we applied OGTT-derived surrogate measures to estimate
the glucose-stimulated insulin response; a method which
has been shown to be superior to the HOMA-B model in
estimating the crucial first phase insulin release [7]. For the
CENTD2 locus, DIAGRAM+ and the present study both
report that CENTD2 mediates its effect through a reduced
beta cell function, whereas we failed to reproduce the effect
of KLF14 on estimates of insulin sensitivity. In the Inter99
Study sample we only have a statistical power of 16% to
find a similar effect size of HOMA-IR for KLF14 as
reported in the DIAGRAM+ paper [2], which might explain
the missing associations in the present study.
Our studies of middle-aged men from the Inter99 cohort
indicate that rs5945326, near DUSP9, may increase risk of
type 2 diabetes through an impairment of glucose-
stimulated insulin release. Yet, the evidence for these
findings is sparse. In DIAGRAM+, the X-chromosome
was only investigated with regard to fasting glucose and
insulin in a subset of the full study population, and no
associations with these traits were reported, nor was any
sex specific association demonstrated. A future meta-
analysis of association signals, GWAS, and additional fine
mapping of the DUSP9 locus with emphasis on this
possible sex specific association will be of interest.
In contrast to CENTD2, where there is no reported
biological data to support an effect on beta cell function,
DUSP9 (which codes for mitogen-activated dual specificity
protein kinase phosphastase-4) has been identified as a gene
involved in insulin signalling and in the pathogenesis of
insulin resistance [8–10].
For the remaining ten loci, with odds ratios of 1.06–1.14,
we found no convincing association to any quantitative
traits related to type 2 diabetes in the Inter99 Study. By
combining data in large meta-analyses, as in the DIA-
GRAM consortium, these new, interesting type 2 diabetes
susceptibility loci were discovered. However, investigations
of intermediary phenotypes with low effect sizes require
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large numbers of individuals. To illustrate this we
performed statistical power analyses in different scenarios
(see ESM Table 2), demonstrating the need for combining
efforts in further meta-analyses when searching for the
diabetes intermediary phenotype.
In conclusion, we report data that support and extend the
findings of an impaired beta cell function in carriers of the
major diabetogenic allele of CENTD2 rs1552224. The
situation regarding the remaining 11 loci calls for further
investigation in large-scale association studies in well-
characterised study populations.
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